William Blair Reiterates Outperform Rating on Rocket Pharmaceuticals (RCKT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
Go back to William Blair Reiterates Outperform Rating on Rocket Pharmaceuticals (RCKT)
May 28, 2025 3:07 PM EDT
JPMorgan analyst Eric Joseph downgraded Rocket Pharmaceuticals (NASDAQ: RCKT) from Overweight to Neutral with a price target of $7.00 (from $44.00).
The analyst comments "We are downgrading RCKT shares to Neutral from Overweight on the back of yesterdays announced clinical hold on lead program RP-A501... More
May 28, 2025 9:35 AM EDT
Goldman Sachs analyst Richard Law downgraded Rocket Pharmaceuticals (NASDAQ: RCKT) from Buy to Sell with a price target of $2.00 (from $13.00).
The analyst comments "On Tuesday (5/27), RCKT announced that the FDA placed a clinical hold on its pivotal Ph. 2 Danon disease (DD) trial. The hold was issued on 5/23 after a patient treated in early May experienced capillary... More
May 28, 2025 5:13 AM EDT
BofA Securities analyst Greg Harrison lowered the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $9.00 (from $32.00) while maintaining a Buy rating.
The analyst comments "Rockets announcement of a death in its RP-A501 phase 2 for rare disorder Danon is tragic on... More
May 27, 2025 8:10 AM EDT
BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $30.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).
The analyst comments "Mgt announced a patient death in Danon trial following capillary leak syndrome sAE, triggering a clinical hold by the FDA. Importantly, the event... More
May 27, 2025 8:07 AM EDT
Jefferies analyst Andrew Tsai reiterated a Buy rating and $29.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).
The analyst comments "We expect significant stock weakness as a Danon patient died due to an acute systemic infection (following an SAE), leading the... More
May 27, 2025 8:06 AM EDT
BofA Securities analyst Greg Harrison lowered the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $32.00 (from $34.00) while maintaining a Buy rating.
The analyst comments "While Rockets incremental 1Q update was likely overshadowed by its late-breaker oral at ASGCT (see below), we were nonetheless encouraged by the progress and continue to like the 2H setup. GAAP EPS was modestly ahead of BB cons (+$0.02), but more... More
May 27, 2025 8:05 AM EDT
Morgan Stanley analyst Michael E Ulz reiterated an Overweight rating and $42.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).
The analyst comments "Ph2 pivotal Danon study on clinical hold due to SAE and subsequent patient death. Rocket announced (PR here) that it had voluntarily paused dosing in its Ph2 study of RP-A501, its AAV9-based gene therapy for the... More
May 27, 2025 8:04 AM EDT
JPMorgan analyst Eric Joseph reiterated an Overweight rating and $44.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).
The analyst comments "In our view, this mornings announcement of a patient death in the pivotal phase 2 study of RP-A501 for Danon Disease and subsequent FDA placed clinical hold represents a major, perhaps... More
May 27, 2025 7:01 AM EDT
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare diseases, today announced an update related to RP-A501, its investigational gene therapy for Danon disease.
A patient participating in the Phase 2 pivotal trial of RP-A501... More
